| Name | Title | Contact Details |
|---|
Osso VR is an award winning VR surgical and medical device training platform. The company is made up of practicing clinicians, professional VR developers and medtech industry veterans. We specialize in hyper-realistic, haptic-enhanced, hands-on interactivity and design.
Beacon Health is a Houston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Roundtrip is the leading digital transportation marketplace for better health outcomes. We provide a simple, comprehensive patient ride ordering software that makes available a community of ride providers who complete the transport. The company is leading the industry in reducing patient no-shows through improved ride management. Roundtrip is built for healthcare professionals — care coordinators, social workers, nurses and other transport requestors —and offers easy-to-use online and mobile platforms that connect patients with non-emergency medical transportation (NEMT). Roundtrip is a comprehensive solution which supports all levels of transport: medical cars, wheelchair vans, stretcher vehicles, ALS/BLS, all payors, and all trips delivered when and where they are needed. Roundtrip is doing more than expanding access to care; we are changing how people manage their health in their everyday lives. As we address social determinants of health and aging in place, Roundtrip is driven to deliver engaged and empowered transportation experiences for our riders.
Tech-Pro Medical Systems is a Mansfield, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Furiex Pharmaceuticals, Inc., a drug development company, engages in the compound partnering business primarily in the United States. It collaborates with pharmaceutical and biotechnology companies to enhance the value of their drug candidates by applying its novel approach to drug development. The company’s products under development include Eluxadoline1, a mu opioid receptor agonist and delta opioid receptor antagonist, which is in Phase III clinical trials for the treatment of diarrhea-predominant irritable bowel syndrome; and Avarofloxacin1, a Phase III-ready fluoroquinolone antibiotic for the treatment of acute bacterial skin and skin structure infections. It is also developing SYR-472, which is in Phase III clinical trials for the treatment of Type-2 diabetes. In addition, the company has rights to compounds in various stages of development and commercialization, which includes Nesina, Liovel, Oseni, and Kazano for the treatment of Type-2 diabetes, as well as Priligy for the treatment of premature ejaculation. The company was founded in 1998 and is headquartered in Morrisville, North Carolina.